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To combat cervical cancer, the United States public health policy has advocated Human 
Papillomavirus (HPV) vaccination for all adolescent females. This female-only HPV vaccination 
campaign has failed to reach sufficiently protective uptake levels. New research describing 
strong associations between HPV and cancers afflicting both sexes, revised cost-effectiveness 
models, and the FDA licensure of a vaccine for men, has led to the inclusion of males into the 
U.S. HPV vaccination campaign. Including men in the ongoing campaign has raised new 
research questions and logistical challenges. Among those, is the challenge of how to effectively 
recruit men into HPV vaccine trials. Communication about HPV infection has been strongly 
linked with female cancers and suffers from sexual stigmatization. This study compared 
conventional recruitment of 18-25 year old men into a clinical HPV vaccination trial with 
recruitment through Facebook Ads™. Facebook Ads™ produced 20% of the study sample. Of 
the 44 men who first heard about the study through social sites, only 13 of these men also heard 
about the study through a conventional recruitment strategy, suggesting that conventional 
recruitment methods can be supplemented by social media recruitment. A larger than expected 
proportion of Facebook recruits were homosexual or bisexual (p=.02) and were also more active 
in social media (p=.02) than expected. The findings of this investigation suggest that Facebook 
and other social platforms could be a useful public health communication and recruitment tool 
for interventions or studies targeting 18-25 year old men, especially those who are homosexual 
or bisexual. 
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Jonathan M. Raviotta, MPH 
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1.0  BACKGROUND 
1.1 HUMAN PAPILLOMAVIRUS PREVENTION: PUBLIC HEALTH OVERVIEW 
Until recently, Human Papillomavirus (HPV) infection was considered a benign, albeit unsightly 
malady responsible for various cutaneous and genital warts. Within the past decade, the medical 
community has escalated the prevention of this previously unremarkable disease to a public 
health priority. The current prevention efforts are an excellent case study of the positive results 
of collaboration among researchers, clinicians, and public health professionals. HPV vaccination 
has emerged as the leading primary prevention strategy to address the compelling public health 
burden of several types of cancer. This vaccination campaign is rapidly evolving in response to 
outcome monitoring and the assimilation of new evidence from epidemiology, virology, 
genetics, and the behavioral sciences. Few other modern health interventions encompass such a 
perfect cross-section of public health practice. 
The discovery of a causal association between HPV and cervical cancer initiated the 
widespread investigation of HPV and has resulted in a proliferation of data that has informed the 
current strategy of vaccination (Koutsky, 2009). Ongoing research continues to shape public 
health interventions in an exciting and dynamic battle with this preventable disease. Similar to 
John Snow’s discovery of the source of cholera, the link between HPV and cervical cancer was 
uncovered by the epidemiologic investigation of a suspected causal agent transmitted through 
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human behavior. As the technology of genetic sequencing advanced through the 1980s it became 
possible to identify HPV DNA within cervical cancers and precancerous lesions. HPV DNA 
from a discrete range of genotypes has now been observed in 100% of cervical cancers. More 
recently, HPV has been implicated in a sizeable proportion of head and neck, penile, and anal 
cancers. Theoretically, eliminating HPV could also eliminate nearly all cervical cancers and 
reduce the incidence of several other cancers, thus saving tens of thousands of lives annually 
(Moscicki, 2008; Plotkin, 2008). 
1.2 HPV BIOLOGY 
Overt symptoms of HPV infection are warts, irritation, pain, and itchiness resulting from 
abnormal changes in the epithelium (Plotkin, 2008). Human Papillomaviruses are a family of 
over 120 identified viruses with a hypothesized equal number of viruses yet to be categorized. 
The characteristic mechanism of action is infection of basal epithelial cells through tissue micro 
trauma. Most strains spontaneously disappear and never result in any overt symptoms of 
infection; however, approximately 20 strains are considered high-risk, with strains 16 and 18 
most frequently associated with cervical cancers. External genital warts are most commonly 
associated with HPV 6 or 11 (Insinga, Liaw, Johnson, & Madeleine, 2008; Wiley & 
Masongsong, 2006). In addition to the high risk mucosal infections, genetically distant yet 
related papillomaviruses are also responsible for foot, hand, and other cutaneous infections 
which range from completely asymptomatic to the appearance of visible warts. Though a prolific 
and diverse group of genotypes, targeted vaccination is possible because of the relatively few 
oncogenic strains. The specific biologic mechanism that separates the low-risk strains from the 
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high-risk strains is not yet explained. However, the persistence of the infection does relate to the 
propensity of a strain to result in cancer. This characteristic may explain why the particularly 
resilient HPV16 is implicated in 50% of cervical cancers worldwide (Plotkin, 2008). 
Several biologic factors specific to HPV argue for immunization over other possible 
interventions. HPV is generally acquired soon after sexual debut and is common among women 
with as few as one lifetime sexual partner (Manhart et al., 2006). The high attack rate and 
infectivity work against other common prevention measures like condoms, and abstinence 
because of the risk of inconsistency and the ability of the virus to infect sites other than those 
commonly protected by physical barriers (Stanley, 2007). Unlike some other sexually 
transmitted diseases, HPV can be transmitted between partners easily during sexual encounters 
other than sexual intercourse. Once infected, the human immune system has a particularly 
difficult time combating persistent HPV strains. Often, the infection is undetected by the immune 
system and in over one half of cases, no antibodies are ever produced. Additionally, 
papillomaviruses are unusually species-specific. This makes research in human analogs virtually 
impossible (Plotkin, 2008). 
1.3 THE PREVALENCE OF DISEASE 
Estimating the prevalence of HPV has been a challenge. HPV is not a reportable disease. New 
cases are not systematically cataloged. The infection may not produce any symptoms, nor result 
in any immediate immune response making the total incidence difficult to quantify. Moreover, 
HPV cannot be reliably cultured so more expensive and complicated DNA and RNA assays are 
required to establish the presence of HPV in a sample  (Koutsky, 1997).  
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Sexually transmitted diseases (STD) are common among United States teens and young 
adults, with 9.1 million new cases of sexually transmitted disease reported annually among 15-24 
year olds. HPV accounts for over half of those reported infections (4.6 million) with an estimated 
prevalence, in 2000, of 9.2 million cases (Weinstock, Berman, & Cates, 2004). Approximately 
75% of the United States population aged 15-49 has clinically detectable evidence of HPV 
infection. One percent of the U.S. population has genital warts, 14% is positive for HPV DNA or 
have had a positive colposcopy, with the remaining 60% testing negative for HPV DNA but 
positive for HPV antibodies (Koutsky, 1997; Wiley & Masongsong, 2006).  
 
Figure 1: Estimated prevalence of genital HPV infection among men and women 15-49 years of age 
in the United States in 1994  
Reprinted with permission (Koutsky, 1997) 
The 2003-2006 National Health and Nutrition Examination Survey (NHANES) included 
collection of self-provided cervicovaginal swab specimens. The prevalence of HPV types 6, 11, 
16, and 18 were reported and found to be associated with age group, education, marital status, 
and sexual behavior. The low-risk types 6 and 11 were most common in the youngest girls (see 
Figure 2). The high-risk types 16 and 18 were most common in young women 20-24 years old 
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who also had the highest overall prevalence (18.5%). A reduction in the prevalence of HPV 
among young women will be an important marker of HPV vaccine effectiveness (Dunne et al., 
2011). 
 
Figure 2: Weighted prevalence of HPV by type and age  
Reprinted with permission (Dunne et al., 2011) 
 
A 2005 review of the literature reports the study population, sample size, and HPV 
prevalence among selected studies of adolescent girls and young women in the United States. 
Prevalence of HPV varied by population and ranged from 14% to 90%. The data are illustrated 
in Figure 3. The samples with the highest prevalence of HPV were drawn from the populations 
of STD clinics and from college students. The authors conclude that these groups should receive 
priority attention in prevention efforts (Revzina & Diclemente, 2005). 
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Figure 3: Study population, study sample size, and reported HPV prevalence of included studies 
Reprinted with permission (Revzina & Diclemente, 2005) 
1.4 THE COST OF HPV INFECTION 
The financial burden of HPV-associated disease is high. In the United States, the estimated 
annual cost of treatment of cervical intraepithelial neoplasia, head and neck malignancies, 
recurrent respiratory papillomatosis (RRP), and genital warts exceeds $7 billion. This excludes 
non-medical indirect costs attributable to infection such as lost work or quality-adjusted life 
years (QALY). One study in the United Kingdom reported an estimation of QALY lost to the 
single malady of genital warts as .0045 years - .023 years. The authors concluded that even this 
benign condition had a substantial enough burden to be included as a factor in economic models 
of HPV prevention (Woodhall et al., 2009). Similarly, among a United States commercially 
insured population in 2004, the cost of genital warts was found to be $647 per episode and $760 
7 
per newly diagnosed case. Adjusted to the US population, the total direct costs due to genital 
warts was $220 million (Hoy, Singhal, Willey, & Insinga, 2009). 
The cost of treatment per case is disproportionately high. Population-based cervical 
cancer screening, multiple follow up visits, high cost of treatments, and frequency of disease, all 
contribute to large economic burden per incidence. For example, the average annual cost of 
treatment and maintenance of diabetes is $1541 per case, while the average cost per episode of 
care for cervical intraepithelial neoplasia is $1709 (Barr & Sings, 2008). Other HPV-attributable 
conditions have also had a measurable financial impact on patients and on the health system. Hu 
and Goldie (2008) found the total lifetime cost of new noncervical HPV-attributable disease 
cases occurring in 2003 to be $418 million. Analysis of the seven major noncervical HPV-
attributable conditions revealed an average discounted lifetime cost per new case ranging from 
$379 for anogenital warts to $54,800 for juvenile-onset recurrent respiratory papillomatosis (Hu 
& Goldie, 2008).  
Compared to other STDs, HPV is second only to HIV in direct medical costs. This 
extraordinary cost is a function of the high lifetime cost per case and the overwhelming number 
of new cases of HPV diagnosed annually. HPV infects more individuals each year than the seven 
other leading STDs combined (see Table 1). In the year 2000, 9.1 million new cases of STDs 
were reported among 15-24 year old Americans. Of the $6.5 billion of direct medical costs 
projected to be incurred from these cases, $2.9 billion will result from HPV (Steben & Duarte-
Franco, 2007).  
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Table 1. Estimated medical costs of 8 STDs in Americans aged 15-24 years 
Reprinted with permission (Steben & Duarte-Franco, 2007) 
STD No. of new cases 
Year 2000 
Average lifetime cost per case 
(US$) 
Total direct medical cost 
(US$) 
HIV 15,000 199,800 3.0 billion 
HPV 4.6 million 1,228 women 
27 men 
2.9 billion 
Genital herpes 640,000 417 women 
511 men 
292.7 million 
Hepatitis B 7,500 779 5.8 million 
Chlamydia 1.5 million 244 women 
20 men 
248.4 million 
Gonorrhea 431,000 266 women 
53 men 
77.0 million 
Trichomoniasis 1.9 million 18 34.2 million 
Syphilis 8,200 444 3.6 million 
Total 9.1 million NA 6.5 billion 
1.5 HPV AND CANCER 
HPV is a causal factor in cervical cancer and is implicated in several other cancers including 
vulvar and vaginal, anal, penile, and head and neck cancers. Though rare, recurrent respiratory 
papillomatosis (RRP) is also caused by HPV and is responsible for high morbidities in infected 
children (Barr & Sings, 2008; Parkin & Bray, 2006). Globally, cancers attributable to HPV 
represent 5.17% or 561,000 potentially preventable cases of cancer (Parkin & Bray, 2006).  
Cervical cancer was the first cancer linked to HPV infection. Since the discovery of this 
association, subsequent investigations of other cancers have revealed connections to HPV, but 
none as overwhelmingly as that of cervical cancer. This fact eventually led to the formulation 
and licensure of a quadrivalent HPV vaccine and the 2007 Advisory Committee on 
Immunization Practices (ACIP) recommendation for routine vaccination of females aged 9-26. 
The committee based its decision on the existing evidence of efficacy in females, the lack of 
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evidence in males, and the results of cost effectiveness modeling within the context of cervical 
cancer (Markowitz et al., 2007). A summary of the cost effectiveness trials cited in the ACIP 
recommendation is presented in Table 2. Though highly variable, these models suggested that 
vaccination could be a cost effective strategy to prevent cervical cancer. Compared with the 
existing strategy of no vaccination, the models predicted the cost of one quality adjusted life year 
(QALY) to range from $3,000 to $24,000 and population level risk reduction of cervical cancer 
from 20% to 75% (Markowitz et al., 2007).  
Table 2: Summary of cost effectiveness models of United States female HPV vaccination program  
Model Markov Markov Dynamic 
Transmission 
Dynamic 
Transmission 
Vaccination Age 12 12 12 <=12 
Vaccine Coverage 100% 70% 70% 70% 
Vaccine Efficacy 90% 75% 90% 90% 
Cost of 
Vaccination 
$377 $400 $400 $360 
Risk Reduction of 
Cervical Cancer 
58% 20% 62% 75% 
Cost per QALY $24,300 $22,800 $14,600 $3,000 
 
As with all computational models, the accuracy of prediction is only as good as the 
estimations of the input parameters and the appropriateness of the model selected. In this case, 
the most influential parameters are vaccination age, population coverage, vaccine efficacy, and 
the cost of vaccination. The model selection is reflected in the reduced cost per QALY and 
higher risk reduction per unit of coverage. The dynamic transmission models incorporate herd 
immunity while the Markov models do not. As the vaccination strategy is implemented, 
variations in any of these parameters will alter the accuracy of the predicted outcomes. A similar 
review conducted by Newall, Beutels, Wood, Edmunds, and MacIntyre (2007) compared four 
models and concluded that routine HPV vaccination could be cost effective. The authors noted 
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the uncertainty of the input parameters and suggested that more models including boys should be 
developed.  
1.6 ENDING HPV: THE UNITED STATES VACCINATION STRATEGY 
The prevalence and inherent biology of HPV transmission make it an ideal candidate for control 
through vaccination. In June 2006, the U.S. Food and Drug Administration (FDA) licensed the 
use of the quadrivalent human papillomavirus (HPV) vaccine GARDASIL™ as produced by 
Merck and Co, Inc. for use in females aged 9-26 years old. In March 2007 the U.S. Centers for 
Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) issued 
recommendations for the vaccine’s use in females as follows:  
The vaccine is administered by intramuscular injection, and the recommended schedule 
is a 3-dose series with the second and third doses administered 2 and 6 months after the first 
dose. The recommended age for vaccination of females is 11--12 years. Vaccine can be 
administered as young as age 9 years. Catch-up vaccination is recommended for females aged 
13--26 years who have not been previously vaccinated. Vaccination is not a substitute for routine 
cervical cancer screening, and vaccinated females should have cervical cancer screening as 
recommended. (Markowitz et al., 2007, p. 1) 
An enormous limitation in the current vaccination strategy has been the lack of routine 
surveillance data related to HPV infection. Fortunately, the United States epidemiologic 
surveillance systems are being modified to provide relevant process and outcome measures. 
Historically, outcomes measurements of HPV prevention and treatment have been inferred from 
routine United States health surveillance of related behaviors like colposcopies, surgical 
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procedures, or rates of vaccine utilization. Table 3 presents the HPV diagnostics added to the 
battery of routine US population surveys. A complete description of each instrument and 
methods of collection for each outcome has been published by Tiro et al. (2008). Going forward, 
researchers will have standardized population-based measures of program effectiveness. 
Table 3: HPV routine surveillance 
 Behavioral 
Risk 
Factor 
Surveillance 
System 
(BRFSS) 
 
Health 
Information 
National 
Trends 
Survey 
(HINTS) 
 
National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES) 
 
National 
Health 
Interview 
Survey 
(NHIS) 
 
National 
Immunization 
Survey (NIS) 
National 
Survey of 
Family 
Growth 
(NSFG) 
National 
Survey of 
Children’s 
Health 
(NSCH) 
Youth Risk 
Behavior 
Surveillance 
System 
(YRBS) 
 
Sexual 
Behavior 
  X   X  X 
HPV 
Vaccine 
Optional 
by State 
X X X X X X  
Pap Test X X  X  X   
HPV Test  X X      
 
Accurately measuring the performance of the United States HPV vaccination program 
has implications beyond reducing the number of cases of cervical cancer. The outcomes of this 
program will also measure the equity of our public health system. Cervical cancer incidence is 
strongly associated with poverty. Women living below the poverty line are three times more 
likely to contract a high risk HPV infection than women who are not poor (Downs, Scarinci, 
Einstein, Collins, & Flowers, 2010). Altering the outcomes of the vaccination program will 
require a thorough understanding of the leverage points at all levels of the social ecological 
framework. Presently, the majority of empirical findings have described factors at the 
interpersonal and intrapersonal levels. The most abundant data describes vaccine acceptability 
and vaccine uptake. Vaccine acceptability describes the willingness to get vaccinated. Vaccine 
uptake is a quantitative measure of individuals completing the three dose series of vaccinations 
(Downs et al., 2010).  
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In a review of the literature, Sheinfeld Gorin, Glenn, and Perkins (2011) examined 
reasons for the lower-than-expected vaccination rates. The summarized literature reported 
potential leverage points in two of the major arms of public health practice; behavioral and 
community health sciences, and health policy and management. Parental attitudes and beliefs 
played a large role in the acceptability of the vaccine. Parents were influenced by real and/or 
perceived barriers, vaccine-related attitudes, perceived approval of family and friends, physician 
recommendation, beliefs about vaccine safety, endemic rates of cervical cancer, level of 
information, and religious background. Health policy and management effects were cost of the 
vaccine, vaccine availability, and the logistical challenges to immunization. 
1.6.1 Female HPV vaccine uptake  
Despite the clinical efficacy of the vaccine (Rambout, Hopkins, Hutton, & Fergusson, 2007), 
effective vaccination against HPV has proven difficult. Five years after the introduction of the 
vaccine, less than half of the eligible female adolescents (44%) initiated the HPV vaccination 
series with only 27% of eligible female adolescents completing the three dose series (Sheinfeld 
Gorin et al., 2011). As compared to the predictive models informing the vaccination strategy, the 
observed rate of vaccination of United States females falls at least 43% below the assumed 
inputs. Moreover, these results are substantially lower than those achieved in other countries. 
Australia almost doubled the U.S. initiation rate among girls with 83% starting the series, and 
Canada surpassed the U.S. initiation rate by 50% (Sheinfeld Gorin et al., 2011). 
Widdice, Bernstein, Leonard, Marsolo, and Kahn (2011) conducted an analysis of the 
records of 3297 9-26 year old female HPV vaccine initiators at Cincinnati Children’s Hospital 
Medical Center. Only 378 patients (11.5%) received all three doses as recommended by the 
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ACIP, and only 27.7% had completed the series within 12 months of initiation. By comparison, 
the 12 month completion rate of the three dose hepatitis B vaccine was 63.4% among 9-12 year 
old girls insured by one of seven managed-care organizations participating in a pooled analysis 
of vaccination. In addition to reporting uptake rates, they also reported significant relationships 
with the predictor variables black race, insurance type, and use of DMPA, an injectable birth 
control method. It is administered every three months. 
Similar results were observed by Chou, Krill, Horton, Barat, and Trimble (2011). Of the 
1,413 girls in their study only 33.2% completed the series within 12 months. Again, private 
insurance and non-black race were significant predictors of completion as was suburban practice 
location. The significant associations with race, insurance, and DMPA suggest weaknesses of the 
current strategy. Racial disparities in uptake suggest systemic problems with the administration 
of the vaccine program. Insurance and DMPA effects are possibly representative of two other 
barriers; cost and timing. 
Schluterman, Terplan, Lydecker, and Tracy (2011) expanded the parsing of uptake 
factors. Similar to other studies, a completion rate of 33% was observed in the population of 
gynecologic patients 9-13 years old at the University of Maryland Medical Center outpatient 
clinic. Additionally, the highest rate of initiation (91%) was observed in the youngest age group 
as compared to 64% in 14 to 17 year old girls and 18% in 18- 26 year old girls. Rates of 
initiation were not associated with race, but rates of completion were significantly predicted by 
white race. Contrariwise, lack of insurance was associated with initiation but not completion.  
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1.6.2 Female HPV vaccine acceptability 
On a per-case basis, vaccination is far less expensive than the existing cervical cancer prevention 
program of screening and cancer treatment. However on a population basis, the expense of 
vaccination is only financially justified and sufficiently protective when the uptake of the 
vaccine is high. If vaccination is used only as a supplement to the existing cervical cancer 
screening protocol, the financial benefits and lives saved will be minimal (Raffle, 2007). A more 
complete understanding of the factors associated with the poor uptake outcomes is necessary to 
improve vaccine coverage. 
The importance of vaccine acceptability is paramount, as HPV vaccination is not 
compulsory. This variability effects both the social/behavioral and policy/management domains 
of the vaccination program. States decide which vaccinations are required for school attendance. 
As several states considered including HPV in the panel of required vaccines, opposing 
constituents argued that this immunization was qualitatively different from other immunizations. 
Opponents against mandatory vaccination argued that HPV is not readily transmissible in the 
school environment and that vaccination would imply institutional consent for adolescent sexual 
behavior, leading to a reduction in the perceived risk of sexual activity and increase in the social 
acceptance of sexual activity. While most pediatricians support universal vaccination, many 
acknowledge that better strategies are necessary to educate parents and overcome the barriers to 
effective immunization (Askelson et al., 2010; Fisher, Darrow, Tranter, & Williams, 2008).  
Allen et al. (2010) published a systematic review of the literature relating to HPV vaccine 
acceptability existing prior to May 2008. Because the majority of these studies were conducted 
prior to vaccine availability, the most commonly reported measures were knowledge, attitudes 
about HPV vaccination, and parental intention to vaccinate their daughters. The authors reported 
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a wide spectrum of research quality. The most notable deficits in the body of research were cited 
as: 
1. High prevalence of measures estimating only awareness and/or knowledge about 
HPV; 
2. Lack of underlying theoretical framework and/or inconsistency with established 
theoretical constructs;  
3. Lack of reliability measures; 
4. Lack of validity measures; and 
5. Homogeneous convenience samples. 
These observations are not surprising, given the immaturity of the HPV immunization program. 
A useful figure of the number of constructs included in the published literature is presented in 
Figure 4. 
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Figure 4: Number of studies measuring specified construct 
Reprinted with permission (Allen et al., 2010) 
In a systematic review of the qualitative literature available from 1995 to 2007, Brewer 
and Fazekas (2007) summarized the findings of 28 studies of HPV-related beliefs and HPV 
vaccine acceptability. The authors categorized study findings into awareness and knowledge 
measures, data within the constructs of the Health Belief Model (HBM), and a miscellaneous 
category of “other factors.” The Health Belief Model is a widely accepted and useful health 
behavior theoretical model that describes an individual’s motivation to perform a specific health 
behavior. The model is composed of six constructs.  
1. Perceived susceptibility to a given condition; 
2. Perceived severity of a given condition; 
3. Perceived benefits of taking actions that will reduce severity or susceptibility; 
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4. Perceived barriers to taking action; 
5. Cues to action from the environment; and 
6. Self-efficacy – the ability to perform the behavior (Glanz, Rimer, & National 
Cancer, 1997). 
The authors noted many of the same methodological limitations as did Allen et al. (2010) and 
discussed conclusions based on the most rigorous evidence. Though many studies measured 
HPV knowledge, the effect of knowledge on uptake remains unknown. In the homogenous 
populations surveyed, United States parents seem to have a favorable perception of HPV 
vaccination despite their lack of information about the vaccine and the disease. The constructs of 
the HBM that had the strongest support were perceived effectiveness (of the vaccine), perceived 
likelihood (of HPV infection), cues to action (physician recommendation), and perceived barriers 
(financial cost and possible increased sexual promiscuity). Though other factors may play an 
important role in vaccine acceptability, the existing literature has not reported sufficient evidence 
to evaluate any possible relationships.  
A more recent literature review from Gamble, Klosky, Parra, and Randolph (2010) 
largely supports the points discussed above. The authors also suggest that future interventions 
should consider adolescent knowledge of HPV, adolescent attitudes toward HPV vaccination, 
and parent/adolescent communication skills (especially relating to sexual topics), in addition to 
physician recommendation, parental knowledge of HPV, and parental attitudes toward HPV 
vaccination. It is clear that, interventions will have to target more than just increasing 
knowledge. Knowledge is only one component of acceptability and acceptability is far from 
uptake (Dempsey, Zimet, Davis, & Koutsky, 2006). 
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1.6.3 Revising the vaccination strategy 
Several program level opportunities to improve the current United States HPV vaccination 
strategy have been identified in the literature. Disparities by race and income have been observed 
in uptake rates. These systematic differences will undermine the effectiveness of the population-
based program and leave at-risk individuals unprotected from HPV infection. Downs et al. 
(2010) suggest the adoption of the socio-ecological model as a framework for implementing the 
HPV vaccination campaign. The socio-ecological model (SEM) or ecological perspective is a 
theoretical model that stratifies interventions into social levels ranging from the intrapersonal 
level to the level of public policy. This perspective suggests that different interventions will 
impact a population cumulatively as the level of intervention is moved away from the individual 
(Glanz et al., 1997). Therefore, disparities will be more likely to be eliminated as more social 
stratifications are included in the vaccination effort. 
Herzog, Huh, and Einstein (2010) agree that policy level dynamics will be critical to 
achieving better uptake rates. Indeed, achieving high levels of acceptability is insufficient if the 
vaccine is not available, one’s physician does not recommend the vaccine, or the vaccine is too 
expensive. At $360, the quadrivalent HPV vaccine GARDASIL™, is the most expensive vaccine 
ever marketed in the United States (Fisher et al., 2008). The affordability of the three dose series 
is a significant barrier to many people even when the cost is subsidized (Schluterman et al., 
2011). Thus, securing funding for the vaccination of the entire US population of pre-adolescent 
girls is a prerequisite to any serious attempt at 100% coverage of eligible children. The 
mechanism in place for funding immunizations to uninsured or underinsured children, is the 
Vaccines for Children (VFC) program. At the discretion of the ACIP, a vaccine can be added to 
the VFC. The program then subsidizes the cost of the vaccine for eligible children. The VFC 
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does not provide vaccinations to individuals 18 years old or older. This may make vaccination 
financially prohibitive for the cohort of young adults that are not vaccinated before age 18 (Khan 
et al., 2008). 
Another logistical barrier that became evident in the female vaccination program, is the 
three dose schedule. The low completion rates of the series suggest that the number or timing of 
doses is problematic to vaccine compliance. Interestingly, the significant association with DMPA 
injections described by Widdice et al. (2011) may support this conclusion. DMPA is injected 
every three months to prevent unwanted pregnancies. The authors suggest that the increased 
contact with the patient, and increased vaccination opportunities provided by the regular visits 
are a logical explanation for the higher than expected completion rates. 
Finally, a conspicuous omission from the original US HPV vaccination policy is the 
entire population of males. Boys were originally excluded from vaccination recommendations 
because GARDASIL™ was not FDA licensed for use in males until October 16, 2009 (Centers 
for Disease & Prevention, 2010). Once a licensed vaccine for boys became available, the United 
States public health leadership was forced to decide if it makes sense to vaccinate boys to 
prevent cervical cancer.  
1.6.4 Rationale for an alternative schedule 
Very little research exists in male HPV vaccination implementation and only a small body of 
knowledge exists from the female program (Nandwani, 2010; Petrovic, Burney, & Fletcher, 
2011; Sheinfeld Gorin et al., 2011), the current study was constructed from the best available 
data in related fields and from lessons learned from the female vaccination program. We 
considered several points especially important to address in the current research design. Among 
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these considerations were the interpersonal and intrapersonal theoretical frameworks that 
influence vaccine uptake, points of similarity and contrast between the male and female 
perceptions of HPV and HPV vaccination, and program implementation dynamics. 
The three dose regimen (0, 2, 6 months) has been reported as significant barrier to 
successful HPV vaccination (Sheinfeld Gorin et al., 2011). In the young adult college population, 
this may be an especially pronounced limitation as only students initiating the vaccination course 
during March, and September-November will have the follow up windows fall within a typical 
school session. As college students have one of the highest prevalence rates of HPV infection, 
reducing the barriers to action in this group is particularly important. 
A possible solution to this timing problem was evaluated in a randomized clinical trial 
among college age women. An alternative dosing schedule of 0, 2, 12 months was compared to 
the standard 0, 2, 6 month protocol. The experimental condition was found to be non-inferior to 
the standard schedule (Zimmerman et al., 2010). This alternate schedule increases the time a 
student could initiate the course of vaccine from four to seven months. Only two months of the 
school calendar would result in vaccine windows that fall during the summer break.  
1.6.5 Including males in The HPV population vaccination strategy 
After GARDASIL™ was licensed by the FDA, the ACIP declined to recommend routine 
vaccination of males instead supporting optional vaccination to prevent genital warts. In the 
policy statement, the ACIP cited mathematical models that suggested routine vaccination of boys 
to be an inefficient use of public health resources (Centers for Disease & Prevention, 2010). 
Eventually, the permission to vaccinate boys was expanded to a recommendation to vaccinate all 
boys age 11 to 12 years old (Schuchat, 2011). 
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 The cost benefit analysis of emerging HPV vaccination trends and the inclusion of 
noncervical cancers were deciding factors in the December 2011 ACIP recommendation to 
routinely vaccinate 11 and 12 year old boys. Original models suggested that the most efficient 
use of public health funds would be to channel resources to female vaccination programs. As the 
uptake rate among females remained poor and population coverage low, revised economic 
models suggested that prophylactic vaccination in boys would more expeditiously protect the 
population  from HPV-related diseases than vaccination of females alone (Barr & Sings, 2008; 
Schuchat, 2011). Further study of noncervical HPV-attributable conditions increased awareness 
of the significant burden of disease that was overshadowed by the focus on cervical cancer. 
While these diseases would be naturally mitigated by campaigns aimed at reducing cervical 
cancer, quantifying the burden of noncervical cancers was useful in compiling more complete 
economic models.  
In 2003 (the year before the vaccine was introduced) the economic burden of noncervical 
HPV disease was estimated at $418 million in direct medical costs (Hu & Goldie, 2008). 
Noncervical cancers that are attributable to HPV infection include cancers of the oropharynx, 
anus, vulva, penis, and vagina. Though a smaller proportion of noncervical cancers are causally 
associated with HPV than cervical cancer, vaccination against HPV would prevent a large 
number of cases. Approximately as many cases of HPV-related noncervical cancers are 
diagnosed each year as cervical cancers; of those cases 50% (approximately 5,000) occur in men. 
While rates of cervical cancer have been declining, the rates of noncervical cancers have been 
increasing (Gillison, Chaturvedi, & Lowy, 2008). These, and similar observations provided more 
data to refine economic models. In December 2011, the ACIP endorsed routine HPV4 
vaccination of males age 11 to 12 years and suggested vaccination of unvaccinated boys and 
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young men age 13 to 21 years. The decision to include males in the routine vaccination 
recommendations was based on safety, efficacy, and computational modeling studies that 
became available after the FDA approval of male vaccination (Schuchat, 2011).  
Estimates of HPV prevalence show similar patterns in men and women. HPV prevalence 
is high in both sexes, even among those at low risk for contracting other STDs. Age stratification 
was also similar in both sexes with young adults showing the highest rates of infection. Samples 
drawn from STD clinics and universities yielded populations of both sexes with the highest rates 
of infection. These disease characteristics suggest that an early age, population-level vaccination 
program would be most effective to prevent HPV transmission (Dunne, Nielson, Stone, 
Markowitz, & Giuliano, 2006; Garland, 2010; Manhart et al., 2006; Revzina & Diclemente, 
2005; Smith, Gilbert, Melendy, Rana, & Pimenta, 2011). However, successful execution of a 
male HPV vaccination campaign may not parallel its female counterpart because of the gender 
specific context of HPV. 
1.6.6 Male HPV vaccination acceptability 
Some preliminary research has been done to clarify the male perspective on HPV vaccination. 
Similar to females, HPV knowledge and health self-efficacy were observed as strong 
independent predictors of vaccine intention (Petrovic et al., 2011). Other factors that have been 
observed to increase vaccine acceptance in males are: 
• Level of sexual activity 
• Perceived susceptibility 
• Perceived severity of infection 
• Perceived benefit of vaccination 
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• Perceived norms 
• Physician recommendation 
• Financial cost  
Assessments of male knowledge of HPV reflect a poor understanding of the disease. Despite the 
recent attention directed to females, accurate knowledge about HPV seems to be an opportunity 
for improvement in both sexes (Nandwani, 2010).  
If one assumes that knowledge of the disease is necessary to motivate action, clinicians 
and educators will have to provide more information to males than females to move boys to 
action in the absence of mandatory vaccination. In studies measuring vaccination acceptance 
after a brief HPV message, most males indicated that they would be willing to get vaccinated. 
The size of the effect was not influenced by the nature of the message. Men were equally likely 
to accept vaccination if the message presented a self-protection or a partner protection message. 
This suggests that perceived susceptibility predicts intention. However, without priming, most 
men do not believe themselves to be susceptible nor do they perceive HPV infection to have 
severe consequences (McPartland, Weaver, Lee, & Koutsky, 2005; Nandwani, 2010). Moreover, 
perceived severity produces only a moderate interest in vaccination. In a study comparing 
messages presenting a vaccine against genital warts alone, or genital warts and either anal, oral, 
or penile cancer, only 60% of participants exposed to the increased severity message were 
willing to be vaccinated. This study also clarifies the nature of the severity message for men, as 
no effect was observed when priming messages included protecting one’s partner from cervical 
cancer (McRee, Reiter, Chantala, & Brewer, 2010).  
A large barrier for many adolescent boys was the context of the ACIP guideline. Many 
insurers, including the Vaccines for Children program, fund only vaccines that are specifically 
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recommended for children. Since the male HPV vaccine was not explicitly recommended, its 
substantial cost was not absorbed by insurers. The 2011 ACIP recommendation bridged this 
barrier for boys, but not necessarily for young men. The cost of the vaccine is especially relevant 
to young adults who may not be able to afford vaccination without coverage by the VFC 
program. While most children would be eligible for at least partial support, the $360 course of 
vaccine is less likely to be covered by the health options available to individuals over 18 
(Sheinfeld Gorin et al., 2011). Testing an Alternative Dosing Schedule 
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2.0  INTRODUCTION 
2.1 INTERNET RECRUITMENT: REVIEW OF THE LITERATURE 
The present study describes the recruitment methods and reports the outcomes of those methods 
during enrollment for the randomized trial testing an alternative HPV dosing schedule in males. 
This study evaluates the results of the Facebook® Ads arm of the recruitment effort as compared 
to the traditional methods recruitment arm.  
Although existing scholarly literature describing and/or evaluating internet recruitment 
campaigns is scarce (Backinger et al., 2008; Gordon, Akers, Severson, Danaher, & Boles, 2006; 
Ramo, Hall, & Prochaska, 2010), the increasing use of the internet and popularity of internet 
media platforms suggests that an online campaign could be a viable recruitment option to 
researchers. A 2009 Pew Research U.S. survey found that 87% of 18-32 year olds access the 
internet or “go online.” Additionally, 67% use social networking sites and 68% get health 
information from the internet (Jones, 2009). The number of Facebook users, at 800 million, 
exceeds the population of almost all countries in the world (Facebook.com, 2011). In a US study 
of male HPV vaccine attitudes, the internet was selected by over one quarter (28.3%) of 
participants as most likely to influence their decision to receive the HPV vaccine (Nandwani, 
2010).  
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Two recent tobacco studies reported outcomes of internet recruitment. A smokeless 
tobacco cessation program compared recruitment from media coverage about the intervention 
(newspaper, radio, and T.V.), online promotion (Google Adwords® campaign and referrals from 
similar websites), and all other methods (paid newspaper ads, direct mailings, and other). The 
results are reported in Table 4. Of the 2,523 participants, the majority (50.6%) were referred 
through media coverage at a cost per recruit of $91.75. The online campaign resulted in over a 
third of enrollments and was more economical. The Google Adwords® campaign yielded 9,155 
clicks. Of those clicks, 511 individuals enrolled, producing a conversion rate of 5.58% at a cost 
of $6.70 per recruit (Gordon et al., 2006). 
Table 4: Tobacco Cessation Recruitment by Source 
Source % of Enrolled Participants Cost per recruit 
Media Coverage 50.6 $91.75 
Online Promotion 34.6 $6.70 
All Other 14.8 $884.14 
 
Ramo et al. (2010) compared three online recruitment tools, ads on Craigslist.org, email 
survey sampling, and paid internet advertisements. Table 5 presents the summary of recruitment 
results. The authors concluded that: 
• Craigslist.org was neither sensitive nor specific, but was cost-effective (generated 
essentially random traffic but was nearly free). 
• Internet advertising was sensitive but not specific (generated willing but not 
eligible traffic at a high cost per participant). 
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• Survey sampling was sensitive, specific, and cost effective (generated willing and 
eligible traffic at a reasonable price). 
Additionally, the authors noted significant differences in several variables among recruitment 
methods. 
Table 5: Summary of Recruitment Methods 
Reprinted with permission (Ramo et al., 2010) 
Recruitment 
method 
 Number 
who 
reached 
survey 
 Number valid 
signed 
consents/screened 
(% of total) 
Number 
meeting 
criteria 
(% of 
total) 
 Number 
providing 
smoking 
data 
(% of 
total) 
Number 
completing 
surveys 
(% of total) 
Cost/ 
participant 
Survey 
sampling 
182 129 (18.2) 76 (22.6) 72 (25.7) 67 (33.3)  $    19.24**  
Internet 
advertising 
4424 450 (63.6) 200 
(59.5) 
156 (55.7) 91 (45.3)  $    42.77  
Craigslist _* 128 (18.1) 60 (17.9) 52 (18.6) 43 (21.4)  $       0.66  
Total >4606 707 336 280 201  
*It was not possible to track how many individuals reached the survey homepage through Craigslist 
but did not indicate whether they consented or did not consent to participate in the survey. 
** Only charged for completed surveys 
2.2 RESEARCH QUESTIONS AND HYPOTHESIS 
The present study was designed to test the effectiveness of the online recruiting of 18-25 
year old young men into the modified HPV vaccination dosing schedule clinical trial. 
Specifically:  
• Can Facebook Ads™ be used to recruit 18-25 year old men into a clinical HPV efficacy 
trial? 
• Do participants recruited through Facebook Ads™ differ systematically from participants 
recruited through conventional sources? 
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To test these questions, we planned recruitment for the clinical trial using conventional recruiting 
mechanisms and Facebook Ads™. The authors tested the hypothesis. 
• Participants referred through online social media would not differ significantly from 
participants referred through conventional recruiting methods on any demographic 
characteristics. 
2.3 THEORETICAL FRAMEWORK  
The research team considered several advertising media and chose to use Facebook Ads™ over 
other online advertising resources because of the unique positioning in a social network. 
Facebook Ads™ are displayed while the viewer is engaged in social behavior. The team believed 
that this placement was congruous with the current research of the theoretical constructs found to 
increase male HPV vaccine acceptance. Using the Health Belief Model as a framework, we 
designed the advertising campaign to be sexually appealing, to increase the perceived norm of 
vaccination by placement in social media, to increase individuals’ self-efficacy of vaccination by 
providing a simple path to enrollment, and to eliminate the financial cost of enrollment by 
funding the vaccine and administration. 
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3.0  METHODS 
The study protocol was approved by the University of Pittsburgh Institutional Review Board on 
September 15, 2010. Shortly thereafter, enrollment was opened and recruitment efforts began in 
earnest. Because the target population was age 18-25 year old males and required four visits to 
the University of Pittsburgh campus, recruitment was focused college campuses within 10 miles 
of the clinical facilities. Both conventional recruitment and online recruitment occurred 
simultaneously at all locations. No attempt was made to limit exposure of either method by 
location. The first eligible screening form was submitted on October 13, 2010. Recruitment was 
completed seven months later on May 4, 2011 when the 220th participant was enrolled in the 
study. 
3.1 RECRUITMENT, ELIGIBILITY SCREENING, AND ENROLLMENT PROCESS 
Recruitment followed the process illustrated in Figure 5 and Figure 6. All print advertisements 
displayed a phone number, email address, and a website. All online advertisements directed 
clicks to an online screening questionnaire. Any person, who called the telephone number or 
contacted the team through email, was given a scripted description of the study protocol (see 
A.1). This script included a brief overview of the study protocol and inclusion criteria. If the 
individual expressed an interest in participating, he was directed to the online screening form. 
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The team was prepared to complete the online process for any individual without access to the 
online screening form.  
The online screening survey (see A.2.2) began with an overview of the study and 
inclusion criteria and ended with the questions, “Does it sound like you might be interested in 
taking part in the study and that you are eligible? Would you be able to commit to four visits at 
UPMC Montefiore CTRC?” If the individual clicked the “yes” button, he was presented with a 
brief 17 question survey to assess eligibility (see A.2.3). This survey was programmed to require 
responses and to evaluate eligibility based on responses. If the individual was assessed as eligible 
for participation, a message confirming his eligibility was displayed, an email dispatched to the 
research team, and he was contacted to schedule his first visit. At that time, the individual was 
assigned a random four digit study ID and randomized into either the standard or experimental 
protocol. Exclusion criteria are presented in Table 6. 
31 
 
Figure 5: Flowchart of recruitment process (personal contact) 
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Figure 6: Flowchart of recruitment process continued (online contact) 
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Table 6: Exclusion Criteria 
Criterion Exclusion for 
Enrollment 
Elimination 
during Study 
<5 sexual partners (i.e., insertive intercourse) X NA 
No other drug studies within 30 days of 
proposed HPV vaccination 
Temporary Temporary 
History of genital warts X NA 
Immunosuppression X X 
No other vaccines within 8 days of proposed 
HPV vaccination 
Temporary Temporary 
No HPV vaccine outside of study ever X X 
Hypersensitivity to yeast or HPV vaccine 
components  
X X 
Known autoimmune disorders X NA 
Hospitalization within last year X NA 
Receipt of immunoglobulins or blood product 
within 90 days of enrollment (may defer until 
90 days completed) 
Temporary Temporary 
Acute moderate or severe illness (may defer 
until well) 
Temporary Temporary 
Serious Adverse Reaction to HPV vaccine X X 
3.1.1 Visit schedule 
The visit timeline was defined by the standard dosing schedule and the alternative dosing 
schedule. Surveys were scheduled to coincide with clinical visits to capture relevant clinical data 
and streamline communication with the participants. Table 7 presents the chronology of the 
study.  
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Table 7: Table of Visits and Surveys 
Visit 1 2 3A 4A 3B 4B 
Timing Day 
0 
Month 
2 
Month 
6 
Month 7 Month 
12 
Month 13 
Target day 0 30-60 182 Visit 3A+14 to 
Visit 3A+49 
365 Visit 3B+14 to 
Visit 3B+49 Window (days) 0 28-70 168-199 
349-
380 
Visit   Group 
A 
Group A Group 
B 
Group B 
Consent       
Exclusion/ 
elimination criteria 
      
Medical history       
Enrollment Survey       
Blood sampling    Group A  Group B 
Pre-Visit Survey   Group 
A  
 Group 
B 
 
Vaccination   Group 
A 
 Group 
B 
 
Post vaccine side 
effect survey 
  Group 
A 
 Group 
B 
 
Exit Survey    Group A  Group B 
 
Both groups followed the same protocol for visits. During the first visit, the potential 
subject provided informed consent, completed the first survey (see B.1.1), and was escorted to 
the Clinical and Translational Research Center (CTRC) at Montefiore Hospital. The CTRC staff 
obtained a medical history, assessed his eligibility for vaccination according to the exclusionary 
criteria in Table 6, collected a blood sample, and administered the first dose of vaccine according 
to the manufacturer’s specifications. He was informed of his group assignment, given 
instructions for follow up scheduling, and provided a Vaccine Information Statement (see A.1.2). 
The second and third visits were completed at the CTRC or The University of Pittsburgh Student 
Health Center, where the participant was screened for exclusionary criteria, and administered the 
second dose of vaccine according to the manufacturer’s specifications. The final visit was 
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conducted at either the CTRC or the Montefiore Outpatient Laboratory where the patient 
provided a blood sample. 
Shortly before the opening of each participant’s second and third vaccination window, he 
was contacted to schedule an appointment. During this encounter he was asked to complete an 
online survey (see B.1.3 Pre-visit 2 & 3 survey). After each successful vaccination was 
confirmed, payment was disbursed and the participant was asked, via email, to complete a brief 
follow up survey to record any adverse events or side effects (see B.1.2 Post-vaccination survey). 
If the participant reported any significant adverse events or side effects, his responses were 
reviewed by the staff medical doctor who provided appropriate follow up instructions. After the 
fourth visit each participant was reminded to complete a final online survey (see B.1.4). Once his 
visit and survey were confirmed, his final payment was disbursed. 
3.1.2 Participant incentive 
Individuals were offered a cash incentive for participation and reminded of the additional 
financial incentives included in the protocol. Cash incentives were paid using the University of 
Pittsburgh WePay system. This mandatory institution-wide system provides a single way for 
researchers at the University of Pittsburgh to pay study participants while maintaing appropriate 
accounting records and insuring participant confidentiality. Each subject was issued a 
MasterCard branded WePay debit card that could be loaded by the research team. The cards 
could be used at any vendor who accepts MasterCard and/or can be redeemed for cash at 
participating banks. The total cash payment for completion of the study was $130.00 and was 
scheduled as follows: 
• Visit 1 $30.00 
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• Visit 2 $10.00 
• Visit 3 $10.00 
• Visit 4 $80.00 
The majority of the payment was weighted after visit four to encourage study completion. 
In addition to the cash payment, participants were also reminded that the vaccine and 
administration were being provided for free. The estimated cost of the three doses of vaccine was 
$360 plus any provider visit costs or copays. This benefit was especially relevant to the 
population as they were all too old to receive benefits from the VFC program. Additionally, male 
HPV vaccination was not widely insured during the time of the study. Finally, participants were 
offered the opportunity to be notified of the results of their final blood analysis. 
3.1.3 Conventional recruitment methods 
Conventional recruitment methods included all methods that did not involve content posted on 
the internet. This included: 
• Advertisements (fliers/posters) posted in on-campus and off-campus locations 
like residence halls, student health centers, student unions, public bulletin board 
sites, coffee shops, academic buildings, and places of business frequented by 
students  
• Fliers distributed at health fairs, classes, sports and other campus events 
• Emails to students, to groups, and to any accessible mailing lists 
• Newspaper advertisements 
• Display ads on city busses 
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• Class announcements 
• Announcements in newsletters 
All printed ads and fliers were designed to be thematically similar. All included a large title, at 
least one image of a young adult or couple, a brief text description of the study, and a phone 
number, email address, and website. Samples are presented in appendix A.3. We selected male 
portraits that represented the target population in age, race, and overall appearance as well as 
female portraits likely to be perceived as attractive by the target population. All conventional 
recruitment methods directed individuals to a phone number, email address, and website where 
eligibility and enrollment procedures were implemented as described in 3.1.1 Visit schedule. 
3.1.4 Facebook Ads™ method 
Facebook Ads™ ran concurrently with conventional recruitment efforts. Ads were purchased 
and formatted using the Facebook Ads™ online interface. During the placement process we 
configured all the parameters necessary to successfully display the ads. As a part of the ads 
system, Facebook provides to advertisers interactive tools that report near real-time ad 
performance and allows adjustment of most parameters. Ad performance was analyzed at least 
weekly and adjustments to placement were made as performance declined.  
The Facebook Ads™ submission process is a multi-step interactive process whereby an 
advertiser selects display options to target the correct audience and minimize cost. This process 
is complex and requires specialized knowledge of social media advertising. The most important 
parameters of the ad campaign are listed in Figure 7 (Facebook.com, 2010). 
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Figure 7: Campaign Performance Glossary  
Reprinted with permission (Facebook.com, 2010) 
 
The first ad (see Figure 8) was placed on November 5, 2010. The daily budget was set at $10 per 
day at a cost per impression of no more than $.32. The audience was specified as Facebook 
users: 
• “Who live in the United States 
• Who live in Pittsburgh PA 
• Exactly between the ages of 18 and 25 inclusive 
• Who are male 
39 
• Who are at Carnegie Mellon, Pittsburgh, Duquesne, RMU, or Point Park 
• Who are single or in a relationship 
• Who speak English (UK), English (Pirate), English (Upside down), or English 
(US) 
• Who are not already connected to Pittvax” (the title of our Facebook page) 
 
Figure 8: First Facebook ad – Red Pointing Guy 
Using these parameters, the estimated reach of the first ad was approximately 80,000 users. The 
ad was monitored daily and quickly supplemented by other ads with different images and/or 
different parameter specifications. During the entire campaign, a total of 15 unique ads were 
placed (see A.4 Sample Facebook Ads). Each ad was monitored and adjusted to yield the highest 
number of clicks possible within the study budget. A click on any ad launched the Online 
screening survey landing page (see A.2.2). 
3.1.4.1 Targeting 
Through the iterative optimization process, we identified two target user groups. One 
group was defined by a long list of keywords thought to be representative of the keywords 
associated with our target population of sexually naïve 18-25 year old males attending college. 
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The list was started by collecting interests through informal interviews with men representative 
of the target population. It was further expanded using keywords supplied by the Facebook 
Ads™ keyword tool. This tool supplied additional keywords that were commonly associated 
with the ones provided as input. The details of the association algorithm are proprietary and were 
not disclosed, however the resulting list seemed to meet face validity. The second group was 
much less specific and was bounded only by sex, age, language, and geography. Isolating these 
two groups provided a convenient way to refresh images periodically to recapture waning 
attention.     
3.1.4.2 Ad composition 
Copy for Facebook Ads™ was extremely limited. The ad was allowed a 25 character title 
and a 135 character body with spaces counted as characters. The domain of the destination URL 
was also displayed as a sub-heading. Four variations of body were created within the limitation 
of the character allowance and IRB approval. 
Each ad was allowed a small image. The same images used for the print ads were used in 
the online ads. The graphic design of the image was adjusted to fit the thumbnail size and 
horizontal orientation while maintaining thematic consistency with the print ads. Samples of the 
ads are presented in Sample Facebook Ads A.4 
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3.2 DATA COLLECTION METHODS 
3.2.1 Facebook metrics 
Facebook Ads™ are integrated with a real-time data dashboard where users can view ad 
performance and make rapid adjustments to the ad placement parameters. This tool was used for 
monitoring ad performance and recording data. The metrics that were most important in the 
ongoing ad campaign were:   
Impressions – the number of times the ad was displayed 
Clicks – the number of times an ad was clicked 
Click through rate – the ratio of impressions to clicks 
Spend – the dollars spent 
Cost per click – the ratio of spend to click 
Of those measures, spend, clicks, and cost per click were used for outcome monitoring and cost 
analysis. A sample of the online dashboard is presented in Figure 9. From these data, we were 
able to determine the number of individuals who were directed to the web survey landing page. 
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Figure 9: Live metrics screenshot image 
3.2.2 Web survey data collection 
Any individual who clicked a Facebook ad or entered the study ad URL manually was directed 
to the web survey landing page. After reading the study description and clicking a button, the 
visitor was presented with the screening survey (see A.2.3 Online screening survey eligibility 
page). Visitors who completed the survey and met the inclusion criteria were assigned a study 
ID. Responses were logged into a database and reported to the research team through an online 
web report. Subsequent surveys were also managed using this procedure. The only variables of 
interest that were collected prior to consent and enrollment were age and referral source. The 
remaining variables were collected during the first visit (see B.2 Variable codebook).  
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3.2.3 Data cleaning and analysis 
Data collected from the online surveys were retrieved from the web reports and imported into 
SPSS version 19.0.0. Cases were merged by study id and examined for duplicate entries. Most 
duplicate entries appeared to be caused by either accidental submission of an incomplete survey, 
or the duplicate submission of an already completed survey. In the case of incomplete 
submission, the entry with more missing values was deleted. In the case of duplicate submission 
of the same survey, the older survey was deleted. Variables were programmatically recoded and 
labeled to facilitate analysis. Frequencies were analyzed to insure correct recoding and labeling.  
Associations between categories were explored with Pearson Chi-square tests. To 
increase expected cell counts and improve test sensitivity, most variable levels were collapsed 
into aggregate groups. For example, age was transformed from eight groups representing one 
year per value to four groups representing two years per value. Likewise, scales like “strongly 
disagree, disagree, agree, strongly agree” were transformed into representative dichotomies like, 
“disagree, agree.” In cases where value consolidation could not produce sufficient expected cell 
counts, Fisher’s exact test was used for 2 X 2 comparisons. For comparisons greater than 2 X 2, 
the Monte Carlo sampling procedure was used to create 99% confidence intervals from 10,000 
samples. Significant cells were identified by conducting z-tests of column proportions. For 
comparisons of more than 2 X 2 variable levels, Bonferroni adjusted p-values were used. Two-
sided significance for tests was established at α=.05. 
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4.0  RESULTS/FINDINGS 
4.1 POPULATION DESCRIPTORS AND DESCRIPTIVE STATISTICS 
4.1.1 Demographics 
A total of 311 men completed the online screening survey and met the inclusion criteria. From 
those, 220 were enrolled on a first come, first served basis. Among the enrolled, age was 
constrained by inclusion criteria to range from 18 to 25 years old inclusive. The mean age was 
21.34 (SD = 2.24). The highest numbers of enrolled men were age 20, 19, or 24 years old. The 
majority of participants were white (80.9% N=178), 12.7% were Asian (N=28), 2.3% were black 
(N=5), and 4.1% selected “other” (N=9). Nine individuals (4.0%) were of Hispanic or Latino 
ethnicity. Sexual orientation data was missing for two individuals. Of the remaining 218, 85% 
were heterosexual (N=187), 9.1% were homosexual (N=20), and 5% were bisexual (N=11). 
Only 9.5% of the enrolled men were not students. Graduate students accounted for 29.5% of 
participants and 60.9% were undergraduate students. The distribution by age and grade is 
presented in Figure 10. All variable frequencies can be found in Appendix B.3. 
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Figure 10: Histogram of enrolled men age 18-25 years old by grade in school 
4.1.2 Referral sources 
Table 8 shows the number of enrolled participants by first referral source and the tabulation of all 
the ways participants heard of the study. Half of the enrolled participants (N=111) first heard 
about the study through a printed ad. Almost a quarter (22.3%) of participants responded to 
social media or electronic message; the remainder first heard from a friend (16.8%) or from an 
announcement (10.5%). Participants were also asked to list all of the ways that they heard about 
the study. A total of 259 advertising impressions were reported. At least one conventional 
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recruiting method touched 85.0% of the participants (N=187), and at least one social media 
method touched 20% of the participants (N=44). Only 5.5% reported hearing about the study 
through both social media and conventional recruitment (N=12). Participants reported the 
number of friends they referred to the study. These referrals produced an additional 151 
recruitment impressions to 109 friends of enrolled participants. Most referrals (68.9%) were 
made in person. 
Table 8: Referral sources of enrolled participants 
 First heard of Study All ways heard of study 
Frequency Percent Frequency Percent 
Flyer 89 40.5 98 37.8 
Facebook or other social networking site 44 20.0 44 17 
Friend(s) talking or texting 37 16.8 56 21.6 
Announcement by faculty/staff 22 10.0 26 10.0 
Ad in newspaper 21 9.5 25 9.7 
Other electronic source 5 2.3 8 3.1 
Bus ad 1 .5 1 .4 
Presentation to student group 1 .5 1 .4 
Total 220 100.0 259 100.0 
4.1.3 Attitudes about participation 
Financial reasons and health reasons were the most important drivers of enrollment. 
Approximately half of the participants cited the free vaccine or incentive payment as the primary 
reason for enrollment with an equal number citing protection from infection for self or others as 
a secondary reason. Combined, “free vaccine, incentive payment, and protect self or others from 
infection” accounted for 84.5% of the primary reason for enrollment and 81.7% of the secondary 
reason for enrollment.  
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Participants were supportive of the project. Ninety percent agreed with the statement, “I 
think this study addresses an important problem in my community.” Ninety-eight percent agreed 
with the statement, “I believe my participation in this study will result in a benefit to others” and 
92.3% agreed with the statement, “I feel like I am an important part of this research project.” 
4.1.4 Social media use among participants 
The 18-25 year old men in this study reported being highly active in social media. Ninety percent 
of participants agreed with the statement, “I stay connected to the people in my life through 
Facebook, Twitter, or another social media service.”  Reading other people’s updates was more 
common than posting updates with 91.8% of participants reporting reading other people’s 
updates at least once a week. Additionally, 64.5% of participants reported reading other people’s 
updates at least once a day. Posting updates was less frequent as 54.5% posted updates at least 
once a week, and 19.5% posted updates at least once a day. At the time of enrollment (October 
2010-May 2011), the majority of participants (84.5%) reported using a computer as their primary 
way to access social networking sites. Only 14.5% reported using a mobile device for primary 
access. 
4.2 MEASURES OF ASSOCIATION 
Demographic and descriptive factors were tested for any significant associations in cross-
tabulations with study variables. Table 9 presents the p-values of the chi-square tests for each 
cross-tab table.  
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Table 9: Study variables compared with demographic variables 
 Grouped 
ages 
White / 
Not White 
Sexual 
Orientation 
How participant first heard about screening survey .02a,c .11c .09c 
Participant heard through a presentation or 
announcement <.00a <.00a,b .39b 
Participant heard through bus or print ad 
0.64 .18b .55b 
Participant heard through other electronic means  
.38c .65b .61b 
Participant heard through at least one social media 
method 
.71 .15 .02a 
Participant heard through at least one conventional 
method 
.76 .53 .03a,b 
Participant heard through both social and 
conventional recruiting methods 
.92c .47b .68b 
First reason enrolled  .26 .03a .06c 
Second reason enrolled  .79 .34 .08 
I feel like I am an important part of this research 
project. 
.32c .36b .46b 
I think this study addresses an important problem in 
my community.  
.61c .56b .51b 
I believe my participation in this study will result in a 
benefit to others.  
.54c .17b 1.0b 
I stay connected to the people in my life through 
Facebook, Twitter, or another social media service. 
.32c .58b .75b 
Over the past month, about how often did you post 
updates?  
.01a 0.46 .02a 
Over the past month, about how often did you read 
other people’s updates?  
.06c .96c .57c 
What is your primary way to access social 
networking sites?  
.16 .32 .03a,b 
a- Significant at p=.05 
b - Fisher's exact test 
c - Fisher's exact test using Monte Carlo sampling with 99% CI 
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4.2.1 Age 
The eight age categories were collapsed into four, 18-19, 20-21, 22-23, 24-25. Significant 
relationships were observed between age and how participants first heard about the study 
(p=.022), having heard through a presentation or class announcement (p=.003), and the 
frequency of posting updates (p=.012). In both of the advertising impression measures, older 
participants were more likely to have heard of the study through a class presentation or 
announcement and younger participants less likely to have heard through that recruitment 
strategy (see Figure 11: Referral sources by age). Among participants who post status updates 
once a day or more, no differences were noted across ages. However, among men who post less 
frequently than once a day, the youngest group posted significantly more status updates than 
expected and the oldest group posted significantly fewer status updates than expected. 
 
Figure 11: Referral sources by age 
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4.2.2 White vs. not white 
Significant associations were identified in the proportion of non-white participants who heard 
about the study in a presentation or announcement (p<.000) and whose primary reason for 
participation was not financial or health (p=.033). Parsing the primary reason for participation 
“other” into the categories, “peer participation” and “help science” resulted in an underpowered 
chi-square with inconclusive results. 
4.2.3 Sexual orientation 
Men who were homosexual or bisexual reported having heard about the study through social 
media more frequently than men who were heterosexual (p=.022). Also, homosexual or bisexual 
men reported fewer impressions of conventional recruitment methods than heterosexual men 
(p=.029), though no particular conventional recruiting method was any less effective than 
another. Homosexual or bisexual participants were significantly more likely than heterosexual 
men to post updates at least once a day (p=.018). Finally, homosexual or bisexual men were 
significantly more likely to use a mobile device rather than a computer as their primary form of 
access to social networking sites while heterosexual men were significantly more likely to use a 
computer rather than a mobile device as their primary access to social networking sites (p=.025).  
4.2.4 Primary and secondary recruitment sources 
The comparison of first recruitment method with all methods of recruitment was significant. 
Participants who first heard about the study through a conventional method were unlikely to have 
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reported also hearing about the study through a social method (p<.000). Of the 176 participants 
who reported first hearing about the study through conventional methods, only 5 reported also 
hearing through social media. Similarly, of the 44 men who first heard about the study through 
social media, only 13 also heard through a conventional source (p<.000). 
 
Figure 12: Overlap of recruiting methods 
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5.0  DISCUSSION 
This study is an important record of recruiting college age men through Facebook Ads™. While 
many researchers may have tried contemporary online recruitment strategies, very little 
published literature discusses these new advertising mediums. A disadvantage of using the peer-
review publication process for communicating findings about emerging technology is the 
temporal lag between investigation and dissemination. In the case of online advertising, this 
delay is long enough to render specific findings or recommendations obsolete. However, the 
persistence of the Facebook platform, emergence of competing social services, and widespread 
integration of internet connectivity into consumer devices ranging from home thermostats, to 
cars, to bathroom scales, seems to argue for the eventuality that online social media advertising 
could become as universally accessible as newspaper, radio, or television advertising. Until that 
time, online recruitment can potentially introduce a selection bias. Any form of internet-based 
communication requires special equipment and skills that may not be normally distributed 
through a population.  
In this study we explored potential selection bias during recruitment of 18-25 year old 
males from a large state university into a clinical vaccination trial. We believed this trial was 
especially well-suited for testing the effectiveness of social media recruitment for the following 
reasons: 
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• We expected that all members of the target population would have equal access to 
both social and conventional media;  
• Young men might be especially difficult to engage publicly through conventional 
recruiting methods given the potential stigma of HPV vaccination; and 
• Online recruiting would allow us to expand recruitment beyond the reach of 
conventional recruitment tools. 
We found that these assumptions were accurate and that Facebook Ads™ were a successful 
supplement to our conventional recruiting methods. 
5.1 ANSWERING THE RESEARCH QUESTIONS 
Our primary research question was, “Can Facebook Ads™ be used to recruit 18-25 year old men 
in a clinical HPV efficacy trial?” At the conclusion of enrollment, 20% of participants first heard 
about the study through Facebook or a social networking site. 31 of those 44 participants did not 
hear about the study through any conventional sources. Thus, social media reached a population 
that would not have been recruited through conventional methods. Facebook Ads™ also reached 
a larger proportion of homosexual or bisexual men than conventional recruitment. This is an 
especially important subpopulation of men within the context of HPV vaccination strategy and 
risk communication. 
Clearly, Facebook Ads™ cannot be used as the sole method of participant recruitment. 
The labor intensive strategy of posting flyers was the most effective means of reaching potential 
recruits. Additionally, the multiplicative impact of social media was not observed in friend 
referral patterns to this study. Part of the appeal of social media advertising is the exponential 
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increase in message exposures gained through social sharing. In this trial, very few participants 
referred friends thorough public social media channels and opted for the more private methods of 
talking to or sending personal messages to friends. As 16.8% of participants first heard about the 
study through a referral from a friend, harnessing the power of social sharing might be a way to 
increase the productivity of an online recruitment campaign. Presumably, there are few other 
topics that could be more difficult to promote through social sharing than the present study of 
HPV vaccination in men. Other recruitment campaigns might find this form of referral much 
easier to utilize with a less stigmatized topic. 
Social media recruitment should be considered by researchers hoping to reach college age 
men. Over 90% of the participants in this trial reported using social media to stay connected with 
their friends and supported that belief by engaging in the specific behavior of reading posts at 
least once a week. Furthermore, 65% reported reading posts at least once a day. Though fewer 
men proactively posted updates, over half of the subjects did so at least weekly. The frequency of 
posting updates seemed to be associated with age. Among those who posted less frequently than 
once per day, younger participants were more active while older participants were less active. 
Age was not significantly associated with the behavior of reading updates, nor on the reported 
use of social media to stay connected with friends, suggesting that older participants still 
consume social media, but are less actively engaged in making contributions.  
Based on the significant finding of association between sexual orientation and social 
media recruitment, we reject the null hypothesis of no effect. We conclude that the sample 
recruited through social media systematically differs from the sample recruited through 
conventional methods. No significant differences were observed in race or age between social 
media vs. conventional recruitment methods. This lack of effect is not evidence for equivalence 
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between the methods, however. Future studies should test these relationships by enrolling more 
non-white participants and further parsing the effect that school attendance may exert on social 
media engagement.  
5.2 ADDITIONAL FINDINGS 
This study also collected useful information to inform HPV vaccination strategies. As the United 
States HPV vaccination campaign has struggled to achieve sufficient uptake, any information 
about leverage points is potentially useful to the evolving public health program. The 
predominant theoretical model used in this program is the Health Belief Model. Application of 
this model is supported by the results of the present study. The top reasons for enrollment in the 
study reflected an awareness of perceived susceptibility (to protect myself or others from 
infection), mitigation of a barrier to action (affordability of the vaccine), and cue to action 
(incentive payment). Additionally, 90.5% of participants believe that HPV is an important 
problem in their community and nearly 100% of participants believed that their participation 
would be beneficial to others. This suggests that efforts to increase perceived severity and 
susceptibility may have had an impact on this population. Other factors like the burdensome 
dosing schedule or expense of the vaccine may be the current barriers to uptake.  
This may not be an accurate assessment of the state of acceptance among all participants, 
however. We observed a significant relationship between non-white participants and selection of 
an alternative reason for participation. This could be a reflection of comparatively lower levels of 
perceived severity/susceptibility, lower perceived cost of vaccination, or an unidentified effect. A 
potential explanation for these results in this study may be attributed to an untested demographic 
56 
factor. A significantly larger proportion of non-white participants were enrolled through 
presentations or announcements. Most of these presentations and announcements were made to 
graduate students in the medical, nursing, and dental schools. While race may have revealed the 
alternative reason for participation, it is entirely possible that the observed effect is confounded 
by curriculum, or another person factor related to graduate education in the health sciences. A 
more purposeful exploration of this dynamic among non-white men could help to reveal 
alternative cues to action, additional social leverage points, or additional perceived benefits to 
vaccination. 
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6.0  CONCLUSION 
The generalizability of this study is limited by the observational methodology. The two 
recruitment conditions were not evaluated empirically as doing so would have harmed the 
primary objective of expeditiously recruiting participants for the clinical vaccination trial. 
Therefore, subjects were not randomly selected from the population. All participants were 
willing to be vaccinated, geographically bound, and likely to be enrolled in college. Hence, their 
attitudes about vaccine acceptance, likelihood of being exposed to recruitment messages, and 
access to social media would not be representative of the broader population. Finally, the small 
sample size limited the specificity of the comparisons between groups. Even within these 
limitations, several interesting relationships were observed. 
College-age men are indeed listening to Facebook Ads™. HPV vaccination proponents, 
public health officials, and researchers hoping to recruit young men, especially homosexual or 
bisexual men, should also take note. In this comparison of Facebook Ads™ recruitment with 
conventional methods of recruitment, Facebook Ads™ were the second most productive 
recruitment strategy yielding 20% of the study sample. The majority of these men were 
untouched by any of the conventional recruitment strategies and therefore represent a population 
that would have been overlooked by conventional recruitment. A larger than expected proportion 
of Facebook recruits were homosexual or bisexual. These men were also more active in social 
media, suggesting that Facebook and other social platforms could be good recruitment sources 
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for studies or interventions targeting homosexual or bisexual young men. Using social media for 
recruitment in studies of less stigmatized subjects and finding ways to increase the use of social 
sharing may increase the effectiveness of social media recruitment ads. 
Application of the Health Belief Model to HPV vaccination strategy is supported by this 
study. The constructs of perceived severity and perceived susceptibility seem to be motivating 
factors for HPV vaccination in this population. Additionally, cost of the vaccine may be a barrier 
to uptake. An incentive payment may be a sufficient cue to action to facilitate HPV vaccination. 
Beyond financial reasons and protection from infection, other factors may be influential in 
increasing HPV vaccine acceptance especially among non-white young men. 
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: RECRUITMENT MATERIALS APPENDIX A
A.1. RECRUITMENT SCRIPTS AND FORMS 
A.1.1. Telephone Script 
Hello, my name is______.  I’m a researcher at the Department of Family Medicine, 
returning your call (e-mail message) about the HPV vaccine study.  May I tell you a little bit 
about our research project? 
The University of Pittsburgh is looking for healthy men aged 18 to 25 to participate in a 
research study where they will receive the federally approved human papilloma virus (or HPV) 
vaccine.  HPV is the cause of genital warts the most common STD in the U.S.  The HPV vaccine 
has been shown to be effective against HPV infection and has been approved by the Federal 
Drug Administration.  It is given as an injection in the upper arm in three separate visits.   
Participants in this research study will visit the Montefiore Hospital Clinical and 
Translational Research Center (CTRC) for a total of four visits over a period of either 7 or 13 
months.  At those visits, participants will receive the HPV vaccine at no cost to them or to their 
health insurance carriers.  In addition, a small amount of blood will be drawn at the first and last 
visits. Volunteers who complete the project will receive a total of $130.00 for their participation 
or the option for an iPod Nano. 
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To be eligible for this study, volunteers should be men 18-25 years old, in good health, 
and planning to return to Pittsburgh next fall.  Volunteers should not have had more than four 
sexual partners or have already had genital warts.   
Does it sound like you might be interested in taking part in this study?  Do you think that 
you are eligible for this study?  Do you think that you would be able to commit to four visits at 
UPMC Montefiore CTRC? 
“No.”  Thank you for your call. 
“Yes.”  Okay, I will set up your first appointment.  They will explain the project to you in 
more detail and if you qualify and are still interested, they will get you started.  
Schedule appointment. 
After setting the appointment:  I will email you the directions. 
61 
A.1.2. GARDASIL™ Vaccine Information Statement 
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A.2. ONLINE RECRUITMENT WEB PAGES 
A.2.1. Online landing page  
https://immunizationed.org/hpvstudy/Default.aspx
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A.2.2. Online screening survey landing page 
https://immunizationed.org/hpvstudy/hpvstudyscreening.aspx 
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A.2.3. Online screening survey eligibility page 
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A.3. SAMPLE PRINT ADS 
A.3.1. Sample flier - african american male 
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A.3.2. Sample flier – white couple 
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A.3.3. Sample newspaper ad – blonde pointing woman 
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A.3.4. Sample bus ad – brunette woman 
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A.4. SAMPLE FACEBOOK ADS 
A.4.1. Sample facebook ad – red pointing guy 
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A.4.2. Sample facebook ad - blue african american guy 
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A.4.3. Sample facebook ad – blonde pointing woman 
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A.4.4. Sample facebook ad – brunette pittsburgh 
 
74 
: DATA APPENDIX B
B.1. DATA COLLECTION WEB PAGES 
B.1.1. Online enrollment survey 
https://immunizationed.org/hpvstudy/hpvstudyvisit1.aspx
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B.1.2. Post-vaccination survey 
https://immunizationed.org/hpvstudy/postvisit.aspx 
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B.1.3. Pre-visit 2 & 3 survey 
https://immunizationed.org/hpvstudy/previsit.aspx 
https://immunizationed.org/hpvstudy/hpvprevisit3.aspx 
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B.1.4. Final survey 
https://www.immunizationed.org/hpvstudy/Visit4Survey.aspx 
 
 
79 
BIBLIOGRAPHY 
Allen, J. D., Coronado, G. D., Williams, R. S., Glenn, B., Escoffery, C., Fernandez, M., . . . 
Mullen, P. D. (2010). A systematic review of measures used in studies of human 
papillomavirus (HPV) vaccine acceptability. [Research Support, N.I.H., Extramural, 
Research Support, U.S. Gov't, P.H.S., Review]. Vaccine, 28(24), 4027-4037. doi: 
10.1016/j.vaccine.2010.03.063 
Askelson, N. M., Campo, S., Lowe, J. B., Dennis, L. K., Smith, S., & Andsager, J. (2010). 
Factors related to physicians' willingness to vaccinate girls against HPV: the importance 
of subjective norms and perceived behavioral control. [Research Support, Non-U.S. 
Gov't]. Women Health, 50(2), 144-158. doi: 10.1080/03630241003705094 
Backinger, C. L., Michaels, C. N., Jefferson, A. M., Fagan, P., Hurd, A. L., & Grana, R. (2008). 
Factors associated with recruitment and retention of youth into smoking cessation 
intervention studies--a review of the literature. [Research Support, Non-U.S. Gov't, 
Review]. Health Educ Res, 23(2), 359-368. doi: 10.1093/her/cym053 
Barr, E., & Sings, H. L. (2008). Prophylactic HPV vaccines: new interventions for cancer 
control. [Review]. Vaccine, 26(49), 6244-6257. doi: 10.1016/j.vaccine.2008.07.056 
Brewer, N. T., & Fazekas, K. I. (2007). Predictors of HPV vaccine acceptability: a theory-
informed, systematic review. [Research Support, Non-U.S. Gov't, Review]. Prev Med, 
45(2-3), 107-114. doi: 10.1016/j.ypmed.2007.05.013 
Centers for Disease, C., & Prevention. (2010). FDA licensure of bivalent human papillomavirus 
vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination 
recommendations from the Advisory Committee on Immunization Practices (ACIP). 
MMWR Morb Mortal Wkly Rep, 59(20), 626-629.  
Chou, B., Krill, L. S., Horton, B. B., Barat, C. E., & Trimble, C. L. (2011). Disparities in human 
papillomavirus vaccine completion among vaccine initiators. [Multicenter Study]. 
Obstetrics & Gynecology, 118(1), 14-20. doi: 10.1097/AOG.0b013e318220ebf3 
Dempsey, A. F., Zimet, G. D., Davis, R. L., & Koutsky, L. (2006). Factors that are associated 
with parental acceptance of human papillomavirus vaccines: a randomized intervention 
study of written information about HPV. [Randomized Controlled Trial, Research 
Support, Non-U.S. Gov't]. Pediatrics, 117(5), 1486-1493. doi: 10.1542/peds.2005-1381 
Downs, L. S., Jr., Scarinci, I., Einstein, M. H., Collins, Y., & Flowers, L. (2010). Overcoming 
the barriers to HPV vaccination in high-risk populations in the US. [Research Support, 
Non-U.S. Gov't, Review]. Gynecol Oncol, 117(3), 486-490. doi: 
10.1016/j.ygyno.2010.02.011 
Dunne, E. F., Nielson, C. M., Stone, K. M., Markowitz, L. E., & Giuliano, A. R. (2006). 
Prevalence of HPV infection among men: A systematic review of the literature. 
80 
[Research Support, U.S. Gov't, P.H.S., Review]. J Infect Dis, 194(8), 1044-1057. doi: 
10.1086/507432 
Dunne, E. F., Sternberg, M., Markowitz, L. E., McQuillan, G., Swan, D., Patel, S., & Unger, E. 
R. (2011). Human papillomavirus (HPV) 6, 11, 16, and 18 prevalence among females in 
the United States--National Health And Nutrition Examination Survey, 2003-2006: 
opportunity to measure HPV vaccine impact? [Research Support, U.S. Gov't, P.H.S.]. J 
Infect Dis, 204(4), 562-565. doi: 10.1093/infdis/jir342 
Facebook.com. (2010). Facebook Help  Retrieved 11/5/10, 2010, from 
https://www.facebook.com/help/?page=173642556024605&ref=bc 
Facebook.com. (2011). Facebook Statistics  Retrieved 11/27/11, 2011, from 
http://www.facebook.com/press/info.php?statistics 
Fisher, R., Darrow, D. H., Tranter, M., & Williams, J. V. (2008). Human papillomavirus vaccine: 
recommendations, issues and controversies. [Review]. Current Opinion in Pediatrics, 
20(4), 441-445. doi: 10.1097/MOP.0b013e328305e298 
Gamble, H. L., Klosky, J. L., Parra, G. R., & Randolph, M. E. (2010). Factors influencing 
familial decision-making regarding human papillomavirus vaccination. [Research 
Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review]. Journal of 
Pediatric Psychology, 35(7), 704-715. doi: 10.1093/jpepsy/jsp108 
Garland, S. M. (2010). Prevention strategies against human papillomavirus in males. [Research 
Support, Non-U.S. Gov't, Review]. Gynecol Oncol, 117(2 Suppl), S20-25. doi: 
10.1016/j.ygyno.2010.01.027 
Gillison, M. L., Chaturvedi, A. K., & Lowy, D. R. (2008). HPV prophylactic vaccines and the 
potential prevention of noncervical cancers in both men and women. [Research Support, 
Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review]. Cancer, 113(10 Suppl), 
3036-3046. doi: 10.1002/cncr.23764 
Glanz, K., Rimer, B. K., & National Cancer, I. (1997). Theory at a glance : a guide for health 
promotion practice. [Bethesda? Md.]: U.S. Dept. of Health and Human Services, Public 
Health Service, National Institutes of Health, National Cancer Institute. 
Gordon, J. S., Akers, L., Severson, H. H., Danaher, B. G., & Boles, S. M. (2006). Successful 
participant recruitment strategies for an online smokeless tobacco cessation program. 
[Research Support, N.I.H., Extramural]. Nicotine Tob Res, 8 Suppl 1, S35-41.  
Herzog, T. J., Huh, W. K., & Einstein, M. H. (2010). How does public policy impact cervical 
screening and vaccination strategies? [Review]. Gynecol Oncol, 119(2), 175-180. doi: 
10.1016/j.ygyno.2010.08.021 
Hoy, T., Singhal, P. K., Willey, V. J., & Insinga, R. P. (2009). Assessing incidence and 
economic burden of genital warts with data from a US commercially insured population. 
[Research Support, Non-U.S. Gov't]. Curr Med Res Opin, 25(10), 2343-2351. doi: 
10.1185/03007990903136378 
Hu, D., & Goldie, S. (2008). The economic burden of noncervical human papillomavirus disease 
in the United States. [Research Support, N.I.H., Extramural, Research Support, U.S. 
Gov't, P.H.S., Review]. American Journal of Obstetrics & Gynecology, 198(5), 500 
e501-507. doi: 10.1016/j.ajog.2008.03.064 
Insinga, R. P., Liaw, K. L., Johnson, L. G., & Madeleine, M. M. (2008). A systematic review of 
the prevalence and attribution of human papillomavirus types among cervical, vaginal, 
and vulvar precancers and cancers in the United States. [Research Support, N.I.H., 
81 
Extramural, Research Support, Non-U.S. Gov't, Review]. Cancer Epidemiol Biomarkers 
Prev, 17(7), 1611-1622. doi: 10.1158/1055-9965.EPI-07-2922 
Jones, S., Fox, Susannah. (2009). Generations Online in 2009: Pew Research Center. 
Khan, K., Curtis, C. R., Ekwueme, D. U., Stokley, S., Walker, C., Roland, K., . . . Saraiya, M. 
(2008). Preventing cervical cancer : overviews of the National Breast and Cervical 
Cancer Early Detection Program and 2 US immunization programs. [Research Support, 
U.S. Gov't, P.H.S., Review]. Cancer, 113(10 Suppl), 3004-3012. doi: 
10.1002/cncr.23765 
Koutsky, L. (1997). Epidemiology of genital human papillomavirus infection. [Review]. Am J 
Med, 102(5A), 3-8. doi: 10.1016/s0002-9343(97)00177-0 
Koutsky, L. (2009). The epidemiology behind the HPV vaccine discovery. [Review]. Annals of 
Epidemiology, 19(4), 239-244. doi: 10.1016/j.annepidem.2009.01.023 
Manhart, L. E., Holmes, K. K., Koutsky, L. A., Wood, T. R., Kenney, D. L., Feng, Q., & Kiviat, 
N. B. (2006). Human Papillomavirus Infection Among Sexually Active Young Women in 
the United States: Implications for Developing a Vaccination Strategy. Sexually 
Transmitted Diseases, 33(8), 502-508 
510.1097/1001.olq.0000204545.0000289516.0000204540a.  
Markowitz, L. E., Dunne, E. F., Saraiya, M., Lawson, H. W., Chesson, H., Unger, E. R., . . . 
Advisory Committee on Immunization, P. (2007). Quadrivalent Human Papillomavirus 
Vaccine: Recommendations of the Advisory Committee on Immunization Practices 
(ACIP). [Practice Guideline]. MMWR Recomm Rep, 56(RR-2), 1-24.  
McPartland, T. S., Weaver, B. A., Lee, S. K., & Koutsky, L. A. (2005). Men's perceptions and 
knowledge of human papillomavirus (HPV) infection and cervical cancer. [Research 
Support, U.S. Gov't, P.H.S.]. J Am Coll Health, 53(5), 225-230. doi: 
10.3200/JACH.53.5.225-230 
McRee, A. L., Reiter, P. L., Chantala, K., & Brewer, N. T. (2010). Does framing human 
papillomavirus vaccine as preventing cancer in men increase vaccine acceptability? 
[Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]. Cancer 
Epidemiol Biomarkers Prev, 19(8), 1937-1944. doi: 10.1158/1055-9965.EPI-09-1287 
Moscicki, A. B. (2008). HPV Vaccines: today and in the Future. [Research Support, N.I.H., 
Extramural, Review]. J Adolesc Health, 43(4 Suppl), S26-40. doi: 
10.1016/j.jadohealth.2008.07.010 
Nandwani, M. C. (2010). Men's knowledge of the human papillomavirus vaccine. [Review]. 
Nurse Pract, 35(11), 32-39. doi: 10.1097/01.NPR.0000388900.49604.e1 
Newall, A. T., Beutels, P., Wood, J. G., Edmunds, W. J., & MacIntyre, C. R. (2007). Cost-
effectiveness analyses of human papillomavirus vaccination. [Research Support, Non-
U.S. Gov't, Review]. The Lancet Infectious Diseases, 7(4), 289-296. doi: 10.1016/S1473-
3099(07)70083-X 
Parkin, D. M., & Bray, F. (2006). Chapter 2: The burden of HPV-related cancers. [Review]. 
Vaccine, 24 Suppl 3, S3/11-25. doi: 10.1016/j.vaccine.2006.05.111 
Petrovic, K., Burney, S., & Fletcher, J. (2011). The relationship of knowledge, health value and 
health self-efficacy with men's intentions to receive the human papillomavirus (HPV) 
vaccine. J Health Psychol, 16(8), 1198-1207. doi: 10.1177/1359105311402861 
Plotkin, S. A., Orenstein, W.A., Offit, P.A. (2008). Vaccines (5th ed.): Elsevier. 
Raffle, A. E. (2007). Challenges of implementing human papillomavirus (HPV) vaccination 
policy. [Review]. BMJ, 335(7616), 375-377. doi: 10.1136/bmj.39273.458322.BE 
82 
Rambout, L., Hopkins, L., Hutton, B., & Fergusson, D. (2007). Prophylactic vaccination against 
human papillomavirus infection and disease in women: a systematic review of 
randomized controlled trials. [Review]. CMAJ Canadian Medical Association Journal, 
177(5), 469-479. doi: 10.1503/cmaj.070948 
Ramo, D. E., Hall, S. M., & Prochaska, J. J. (2010). Reaching young adult smokers through the 
internet: comparison of three recruitment mechanisms. [Comparative Study, Research 
Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]. Nicotine Tob Res, 
12(7), 768-775. doi: 10.1093/ntr/ntq086 
Revzina, N. V., & Diclemente, R. J. (2005). Prevalence and incidence of human papillomavirus 
infection in women in the USA: a systematic review. [Review]. International Journal of 
Std & Aids, 16(8), 528-537. doi: 10.1258/0956462054679214 
Schluterman, N. H., Terplan, M., Lydecker, A. D., & Tracy, J. K. (2011). Human papillomavirus 
(HPV) vaccine uptake and completion at an urban hospital. Vaccine, 29(21), 3767-3772. 
doi: 10.1016/j.vaccine.2011.03.032 
Schuchat, A. (2011). ACIP recommends all 11-12 year-old males get vaccinated against HPV. 
Press Release Archive. CDC Online Newsroom: U.S. Department of Health and Human 
Services. 
Sheinfeld Gorin, S. N., Glenn, B. A., & Perkins, R. B. (2011). The human papillomavirus (HPV) 
vaccine and cervical cancer: uptake and next steps. [Review]. Adv Ther, 28(8), 615-639. 
doi: 10.1007/s12325-011-0045-x 
Smith, J. S., Gilbert, P. A., Melendy, A., Rana, R. K., & Pimenta, J. M. (2011). Age-specific 
prevalence of human papillomavirus infection in males: a global review. [Research 
Support, N.I.H., Extramural, Review]. J Adolesc Health, 48(6), 540-552. doi: 
10.1016/j.jadohealth.2011.03.010 
Stanley, M. (2007). Prevention strategies against the human papillomavirus: the effectiveness of 
vaccination. [Review]. Gynecol Oncol, 107(2 Suppl 1), S19-23. doi: 
10.1016/j.ygyno.2007.07.068 
Steben, M., & Duarte-Franco, E. (2007). Human papillomavirus infection: epidemiology and 
pathophysiology. [Review]. Gynecol Oncol, 107(2 Suppl 1), S2-5. doi: 
10.1016/j.ygyno.2007.07.067 
Tiro, J. A., Saraiya, M., Jain, N., Liddon, N., Cokkinides, V., Lai, S. M., . . . Wideroff, L. (2008). 
Human papillomavirus and cervical cancer behavioral surveillance in the US. [Research 
Support, U.S. Gov't, P.H.S., Review]. Cancer, 113(10 Suppl), 3013-3030. doi: 
10.1002/cncr.23760 
Weinstock, H., Berman, S., & Cates, W., Jr. (2004). Sexually Transmitted Diseases among 
American Youth: Incidence and Prevalence Estimates, 2000. Perspectives on Sexual and 
Reproductive Health, 36(1), 6-10.  
Widdice, L. E., Bernstein, D. I., Leonard, A. C., Marsolo, K. A., & Kahn, J. A. (2011). 
Adherence to the HPV vaccine dosing intervals and factors associated with completion of 
3 doses. [Research Support, N.I.H., Extramural]. Pediatrics, 127(1), 77-84. doi: 
10.1542/peds.2010-0812 
Wiley, D., & Masongsong, E. (2006). Human papillomavirus: the burden of infection. [Review]. 
Obstet Gynecol Surv, 61(6 Suppl 1), S3-14. doi: 10.1097/01.ogx.0000221010.82943.8c 
Woodhall, S. C., Jit, M., Cai, C., Ramsey, T., Zia, S., Crouch, S., . . . Lacey, C. J. N. (2009). Cost 
of Treatment and QALYs Lost Due to Genital Warts: Data for the Economic Evaluation 
83 
of HPV Vaccines in the United Kingdom. Sexually Transmitted Diseases, 36(8), 515-521 
510.1097/OLQ.1090b1013e3181a1074c1092c.  
Zimmerman, R. K., Nowalk, M. P., Lin, C. J., Fox, D. E., Ko, F. S., Wettick, E., . . . Michaels, 
M. (2010). Randomized trial of an alternate human papillomavirus vaccine administration 
schedule in college-aged women. [Comparative Study, Randomized Controlled Trial, 
Research Support, Non-U.S. Gov't]. J Womens Health (Larchmt), 19(8), 1441-1447. doi: 
10.1089/jwh.2009.1753 
 
 
